Get the Stockscreener App
5.83
2.18%
-0.13
Engene Holdings Inc stock is traded at $5.83, with a volume of 99,164.
It is down -2.18% in the last 24 hours and down -22.27% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$5.96
Open:
$6.54
24h Volume:
99,164
Relative Volume:
0.49
Market Cap:
$297.19M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-26.70M
1W Performance:
-4.11%
1M Performance:
-22.27%
6M Performance:
-33.07%
1Y Performance:
-18.23%
1-Day Range:
$5.60
$6.54
1-Week Range:
$5.60
$6.55
52-Week Range:
$4.42
$18.40
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
5.83 | 297.19M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Holdings Inc Stock (ENGN) Latest News
Engene Holdings Faces Regulatory Challenges and Business Risks Amid Clinical Trial Hurdles - TipRanks
enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why - MSN
enGene Holdings inks $100M share sale deal with Jefferies - Investing.com
EnGene : Material Agreement Form 8 K - Marketscreener.com
Form 424B5 enGene Holdings Inc. - StreetInsider.com
EnGene Holdings Inc. Reports Earnings Results for the Full Year Ended October 31, 2024 - Marketscreener.com
enGene Reports Full Year 2024 Financial Results and Provides a Business Update - BioSpace
(ENGN) Technical Pivots with Risk Controls - Stock Traders Daily
enGene Holdings Inc. (ENGN) reports earnings - Quartz
enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
enGene Reports Promising 71% Response Rate in Bladder Cancer Trial, Strong $298M Cash Position - StockTitan
enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook (NASDAQ:ENGN) - Seeking Alpha
Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks - MSN
(ENGN) Investment Analysis - Stock Traders Daily
Point72 Asset Management L.P. Has $4.38 Million Holdings in enGene Holdings Inc. (NASDAQ:ENGN) - MarketBeat
enGene’s (ENGN) Market Outperform Rating Reiterated at JMP Securities - Defense World
enGene's (ENGN) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN) - Defense World
Contrasting Immunovant (NASDAQ:IMVT) and enGene (NASDAQ:ENGN) - Defense World
Raymond James Initiates Coverage of enGene Holdings (ENGN) with Outperform Recommendation - MSN
enGene (NASDAQ:ENGN) Earns Outperform Rating from Analysts at Raymond James - MarketBeat
Recent uptick might appease enGene Holdings Inc. (NASDAQ:ENGN) institutional owners after losing 4.2% over the past year - Simply Wall St
enGene to Participate in Upcoming Investor Conferences - Vulcan Advocate
enGene Holdings to Present Cancer Treatment Updates at Major Healthcare Conferences - StockTitan
enGene (NASDAQ:ENGN) Coverage Initiated at JMP Securities - MarketBeat
JMP bullish on Engene stock as non-viral bladder cancer therapy gains traction By Investing.com - Investing.com South Africa
JMP bullish on Engene stock as non-viral bladder cancer therapy gains traction - Investing.com India
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
(ENGN) Trading Advice - Stock Traders Daily
With 52% ownership of the shares, enGene Holdings Inc. (NASDAQ:ENGN) is heavily dominated by institutional owners - Yahoo Finance
Blue Owl Capital Holdings LP Increases Stake in enGene Holdings Inc - GuruFocus.com
enGene files $300M mixed securities shelf - TipRanks
enGene Holdings Inc. (NASDAQ:ENGN) Receives $33.67 Consensus PT from Brokerages - MarketBeat
How the (ENGN) price action is used to our Advantage - Stock Traders Daily
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - BioSpace
enGene to Present Breakthrough Cancer Therapy at Guggenheim Healthcare Conference - StockTitan
Forbion growth opportunities fund acquires $4.99m in Engene Holdings shares - Investing.com Australia
Forbion growth opportunities fund acquires $4.99m in Engene Holdings shares By Investing.com - Investing.com South Africa
FY2024 EPS Estimates for enGene Boosted by Leerink Partnrs - MarketBeat
EnGene Announces $60 Million Private Placement Financing - Marketscreener.com
enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Growth in Short Interest - MarketBeat
enGene secures $60 million in private placement By Investing.com - Investing.com Canada
enGene Announces $60 Million Private Placement Financing - citybiz
Why enGene Holdings Stock Is Trading Higher - Benzinga
enGene secures $60 million in private placement - Investing.com
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Engene Holdings Inc Stock (ENGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
| Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 29 '23 |
Buy |
9.06 |
10,020 |
90,771 |
2,017,820 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 28 '23 |
Buy |
7.69 |
5,050 |
38,827 |
2,007,800 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 27 '23 |
Buy |
7.17 |
2,750 |
19,711 |
2,002,750 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):